Filing Flows › Comparisons › CBIO vs ABUS
Crescent Biopharma vs Arbutus Biopharma: CBIO and ABUS compared
Crescent Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q1 2026) against $1.0M for Arbutus Biopharma (Q2 2026).
Where the money goes: CBIO and ABUS
Crescent Biopharma (CBIO) · Q1 2026
Crescent Biopharma, Q1 2026: revenue $1.0M, net loss $23.3M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Arbutus Biopharma (ABUS) · Q2 2026
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Crescent Biopharma (CBIO) | Arbutus Biopharma (ABUS) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $1.0M | $1.0M |
| Revenue growth, Y/Y | — | -91% |
| Operating margin | n/m | -588.2% |
| Net earnings | −$23.3M | −$5.1M |
| Net margin | — | -507.2% |
| Operating cash flow | −$8.9M | −$6.0M |
Where the revenue comes from
Arbutus Biopharma
- Revenue from collaborations and licenses: $632K (62%)
- Collaborations and licenses: $202K (20%)
- Non-cash royalty revenue: $180K (18%)
Questions
Which is bigger, Crescent Biopharma or Arbutus Biopharma?
Crescent Biopharma is the larger company: $1.0M of revenue in its latest quarter (Q1 2026) against $1.0M for Arbutus Biopharma (Q2 2026).
More: Crescent Biopharma earnings · how Crescent Biopharma makes money · Arbutus Biopharma earnings · how Arbutus Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Apr 29, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.